Dr. Goldberg has more than 30 years of experience in the pharmaceutical and biotechnology industries, ranging from drug discovery at a Fortune 25 company to chief executive officer of “virtual” biotechnology companies. Dr. Goldberg has served as President, CEO and Founder of Lipimetix Development, Inc., President, CEO and co-Founder of Transport Pharmaceuticals, Inc., President, and co-Founder of Benu BioPharma., a biotechnology management and consulting company, President, CEO and Director of BZL Biologics, a company developing monoclonal antibodies for the treatment of prostate cancer. The BZL antibody technology was licensed by Millennium Pharmaceuticals (NASDAQ:MLNM). Dr. Goldberg was President, CEO and co-Founder of Talaria Therapeutics, which developed the Large Unilamellar Vesicle (LUV) technology. Talaria Therapeutics was acquired by Esperion Therapeutics (NASDAQ:ESPR) less than two years after its formation.

Dr. Goldberg was also Vice President of Product Development and regulatory Affairs at GelTex Pharmaceuticals (NASDAQ:GELX), where he was responsible for all biological and clinical development activities at the company, leading to the approval of RenaGel® and WelChol®. He was also co-Founder of Transcend Therapeutics, a spin out of Clintec Nutrition Co. (a joint venture between Baxter and Nestle), where he was Vice President of Research and Development, and Science Coordinator for the Atherosclerosis Research Program at Pfizer Central Research. Dr. Goldberg holds a Ph.D. in Physiology and Biochemistry from Temple University and received post doctoral training at the University of Pennsylvania and at the Specialized Center of Research on Atherosclerosis, University of California, San Diego. He is a Fellow of the American Heart Association. He has published extensively in basic and clinical sciences and is the inventor on thirteen U.S. patents.

​